Compare WRAP & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WRAP | ENTX |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.7M | 142.0M |
| IPO Year | N/A | 2018 |
| Metric | WRAP | ENTX |
|---|---|---|
| Price | $2.50 | $2.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 453.5K | 74.3K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,133,000.00 | $124,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 25.25 |
| 52 Week Low | $1.20 | $1.50 |
| 52 Week High | $3.00 | $3.22 |
| Indicator | WRAP | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.98 | 40.14 |
| Support Level | $2.63 | $2.07 |
| Resistance Level | $3.00 | $2.27 |
| Average True Range (ATR) | 0.22 | 0.19 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 51.22 | 15.44 |
Wrap Technologies Inc is a public safety technology and services company that delivers safe and effective policing solutions to law enforcement and security personnel worldwide. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.